Factors associated with extremely poor visual outcomes in patients with central retinal vein occlusion.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 11 2020
Historique:
received: 30 07 2020
accepted: 19 10 2020
entrez: 13 11 2020
pubmed: 14 11 2020
medline: 29 12 2020
Statut: epublish

Résumé

Here, we examined prognostic factors for extremely poor visual outcomes in patients with central retinal vein occlusion (CRVO) in actual practices. We included 150 consecutive eyes with treatment-naïve acute CRVO from four different facilities and observed them for over 24 months. Macular edema (ME) was treated with one or three monthly anti-vascular endothelial growth factor injections (1 or 3 + pro re nata). According to the final Snellen visual acuity (VA), we divided the patients into very poor VA (< 20/200) and control (≥ 20/200) groups and examined risk factors for poor final visual outcomes. The baseline Snellen VA was hand motion to 20/13. The mean number of anti-VEGF injections for ME was 5.3 ± 3.7 during the follow-up period. In total, 49 (32.7%) patients exhibited a very poor final VA; this group comprised significantly older patients with a significantly poorer baseline VA (P < 0.01 for both) than the control group. Comorbid internal carotid artery disease and diabetic retinopathy were significantly associated with a poor final VA. In actual clinical practice, visual outcomes may be extremely poor despite ME treatment in certain patients with CRVO, with advanced age, poor baseline VA, and comorbid internal carotid artery disease and diabetic retinopathy being significant risk factors.

Identifiants

pubmed: 33184484
doi: 10.1038/s41598-020-76840-6
pii: 10.1038/s41598-020-76840-6
pmc: PMC7665063
doi:

Substances chimiques

VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19667

Références

Ophthalmology. 1983 May;90(5):488-506
pubmed: 6192376
Retina. 2014 Sep;34(9):1728-35
pubmed: 24914476
Arch Ophthalmol. 1996 May;114(5):545-54
pubmed: 8619763
Br J Ophthalmol. 2018 Aug;102(8):1066-1071
pubmed: 29699979
Br J Ophthalmol. 1965 Dec;49(12):626-45
pubmed: 4954984
Am J Ophthalmol. 1971 Nov;72(5):998-1011
pubmed: 5315812
Arch Ophthalmol. 2008 Apr;126(4):513-8
pubmed: 18413521
Sci Rep. 2019 Apr 25;9(1):6569
pubmed: 31024035
Retina. 2018 Feb;38(2):272-282
pubmed: 28221256
Ophthalmology. 2010 Jun;117(6):1124-1133.e1
pubmed: 20381871
Arch Ophthalmol. 1997 Apr;115(4):486-91
pubmed: 9109757
Am J Ophthalmol. 2019 Aug;204:62-69
pubmed: 30862502
BMJ Open Ophthalmol. 2020 Mar 24;5(1):e000423
pubmed: 32258421
Ophthalmology. 2011 Jan;118(1):119-133.e1-2
pubmed: 20723991
Ophthalmology. 2011 Oct;118(10):2041-9
pubmed: 21715011
Invest Ophthalmol Vis Sci. 1986 Dec;27(12):1706-12
pubmed: 2947873
Am J Ophthalmol. 2016 Aug;168:260-268
pubmed: 27296489
Retina. 2018 Aug;38(8):1571-1580
pubmed: 28671896
Arch Ophthalmol. 1993 Aug;111(8):1087-95
pubmed: 7688950
Am J Ophthalmol. 2013 Mar;155(3):429-437.e7
pubmed: 23218699
Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2708-2716
pubmed: 29860457
Ophthalmol Retina. 2018 Feb;2(2):134-142
pubmed: 31047340
Ophthalmology. 1983 May;90(5):458-74
pubmed: 6877778
Br J Ophthalmol. 2013 Mar;97(3):278-84
pubmed: 23298885
Ophthalmology. 2016 May;123(5):1101-11
pubmed: 26896124
Ophthalmology. 2012 May;119(5):1024-32
pubmed: 22440275
Ophthalmology. 1983 May;90(5):481-3
pubmed: 6877780

Auteurs

Daisuke Nagasato (D)

Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo, Japan.
Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

Yuki Muraoka (Y)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shougoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. muraoka@kuhp.kyoto-u.ac.jp.

Rie Osaka (R)

Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan.

Yuko Iida-Miwa (Y)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shougoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Yoshinori Mitamura (Y)

Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

Hitoshi Tabuchi (H)

Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo, Japan.

Shin Kadomoto (S)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shougoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Tomoaki Murakami (T)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shougoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Sotaro Ooto (S)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shougoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Kiyoshi Suzuma (K)

Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan.

Akitaka Tsujikawa (A)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, 54 Shougoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH